105 related articles for article (PubMed ID: 38733987)
1. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.
van Eijck CWF; Real FX; Malats N; Vadgama D; van den Bosch TPP; Doukas M; van Eijck CHJ; Mustafa DAM;
Cell Rep Med; 2024 May; 5(5):101557. PubMed ID: 38733987
[TBL] [Abstract][Full Text] [Related]
2. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer.
Duan K; Jang GH; Grant RC; Wilson JM; Notta F; O'Kane GM; Knox JJ; Gallinger S; Fischer S
Sci Rep; 2021 Jul; 11(1):14951. PubMed ID: 34294813
[TBL] [Abstract][Full Text] [Related]
3. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
[TBL] [Abstract][Full Text] [Related]
4. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
6. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
7. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
Kuwabara S; Tsuchikawa T; Nakamura T; Hatanaka Y; Hatanaka KC; Sasaki K; Ono M; Umemoto K; Suzuki T; Sato O; Hane Y; Nakanishi Y; Asano T; Ebihara Y; Kurashima Y; Noji T; Murakami S; Okamura K; Shichinohe T; Hirano S
Cancer Sci; 2019 Jun; 110(6):1853-1862. PubMed ID: 30997706
[TBL] [Abstract][Full Text] [Related]
9. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma.
de Andrés MP; Jackson RJ; Felipe I; Zagorac S; Pilarsky C; Schlitter AM; Martinez de Villareal J; Jang GH; Costello E; Gallinger S; Ghaneh P; Greenhalf W; Knösel T; Palmer DH; Ruemmele P; Weichert W; Buechler M; Hackert T; Neoptolemos JP; Notta F; Malats N; Martinelli P; Real FX
Gut; 2023 Mar; 72(3):535-548. PubMed ID: 36109153
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.
van Eijck CWF; Mustafa DAM; Vadgama D; de Miranda NFCC; Groot Koerkamp B; van Tienhoven G; van der Burg SH; Malats N; van Eijck CHJ;
Gut; 2024 Jan; 73(2):311-324. PubMed ID: 37709493
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
12. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer.
Kloesch B; Ionasz V; Paliwal S; Hruschka N; Martinez de Villarreal J; Öllinger R; Mueller S; Dienes HP; Schindl M; Gruber ES; Stift J; Herndler-Brandstetter D; Lomberk GA; Seidler B; Saur D; Rad R; Urrutia RA; Real FX; Martinelli P
Gut; 2022 Apr; 71(4):766-777. PubMed ID: 33846140
[TBL] [Abstract][Full Text] [Related]
13. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
[TBL] [Abstract][Full Text] [Related]
14. GATA6-AS1 suppresses epithelial-mesenchymal transition of pancreatic cancer under hypoxia through regulating SNAI1 mRNA stability.
Zhou Y; Zhou X; Ben Q; Liu N; Wang J; Zhai Y; Bao Y; Zhou L
J Transl Med; 2023 Dec; 21(1):882. PubMed ID: 38057853
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
16. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
[TBL] [Abstract][Full Text] [Related]
18. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.
Martinelli P; Carrillo-de Santa Pau E; Cox T; Sainz B; Dusetti N; Greenhalf W; Rinaldi L; Costello E; Ghaneh P; Malats N; Büchler M; Pajic M; Biankin AV; Iovanna J; Neoptolemos J; Real FX
Gut; 2017 Sep; 66(9):1665-1676. PubMed ID: 27325420
[TBL] [Abstract][Full Text] [Related]
19. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy.
Kokumai T; Omori Y; Ishida M; Ohtsuka H; Mizuma M; Nakagawa K; Maeda C; Ono Y; Mizukami Y; Miura S; Kume K; Masamune A; Morikawa T; Unno M; Furukawa T
Mod Pathol; 2023 May; 36(5):100102. PubMed ID: 36788090
[TBL] [Abstract][Full Text] [Related]
20. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
Front Immunol; 2021; 12():649061. PubMed ID: 33986743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
